A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system
Authors:
Open Access
- 1 April 2013
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 2 (4) , e23639
Abstract
Bispecific T-cell engagers (BiTEs) may break multiple barriers that currently limit the use of immunotherapy in glioblastoma patients. We have recently described a novel BiTE specific for a mutated form of the epidermal growth factor receptor, EGFRvIII, that exerts potent antineoplastic effects against established invasive tumors of the brain.Keywords
This publication has 10 references indexed in Scilit:
- Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral gliomaProceedings of the National Academy of Sciences, 2012
- T cells become licensed in the lung to enter the central nervous systemNature, 2012
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomabBlood, 2012
- Adoptive immunotherapy for cancer: harnessing the T cell responseNature Reviews Immunology, 2012
- Bispecific antibodies engage T cells for antitumor immunotherapyExpert Opinion on Biological Therapy, 2011
- EGFRvIII‐Targeted Vaccination Therapy of Malignant GliomaBrain Pathology, 2009
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging AntibodyScience, 2008
- A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsProceedings of the National Academy of Sciences, 2007
- Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cellsNature Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005